BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
2.870
0.00 (0.00%)
Jan 14, 2026, 4:00 PM EST - Market closed
BioLineRx Revenue
BioLineRx had revenue of $427.00K in the quarter ending September 30, 2025, a decrease of -91.36%. This brings the company's revenue in the last twelve months to $12.74M, down -42.09% year-over-year. In the year 2024, BioLineRx had annual revenue of $28.94M with 502.92% growth.
Revenue (ttm)
$12.74M
Revenue Growth
-42.09%
P/S Ratio
0.97
Revenue / Employee
$454,821
Employees
28
Market Cap
12.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.94M | 24.14M | 502.92% |
| Dec 31, 2023 | 4.80M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BLRX News
- 7 weeks ago - BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 - PRNewsWire
- 2 months ago - BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types - PRNewsWire
- 3 months ago - BioLineRx Ltd. - Special Call - Seeking Alpha
- 3 months ago - BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers - PRNewsWire
- 5 months ago - BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 months ago - BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire